Sacituzumab - An Overview
are higher when compared with current cefepime breakpoints, increased breakpoints of cefepime/zidebactam may be warranted for AcinetobacterThe stability of cefepime in opposition to AmpC, when coupled with an ESBL-Lively BLI, supplies the coverage of AmpC and ESBL coproducers, which might be increasingly found. Cefepime mixtures with BLIs getting c